Latest autoimmune diseases Stories

More People Seeking Help for Eczema and Psoriasis

2013-05-16 23:32:49

As the prevalence of eczema grows and consumers seek affordable ways to cope with recurring skin issues, TriDerma launches its Eczema Fast Healing™ and Psoriasis Control™ creams into the First Aid section of drugstores and supercenters nationwide. TriDerma becomes part of wider trend of pharmacy health and wellness programs. Anaheim, CA (PRWEB) May 16, 2013 TriDerma announced that it has added Eczema Fast Healing™ and Psoriasis Control™ to the First Aid assortment at pharmacies...

AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease

2013-05-17 00:20:17

First selective JAK1 inhibitor to enter Phase 2 studies in Crohn's disease NORTH CHICAGO, Ill. and MECHELEN, Belgium, May 17, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. Upon successful completion of the...

Neuracel Hits the Market - Aims To Provide A Natural Remedy For Diabetic Peripheral Neuropathy

2013-05-16 23:04:04

A company known for its natural approach to treating various ailments, Neuracel has launched its latest product, called the Ultimate Neuropathy Support System at http://www.neuracel.com. With this product, the company hopes to provide a treatment for peripheral neuropathy that is not only effective, but also natural. Boise, ID (PRWEB) May 16, 2013 A disorder of the nerves, Diabetic Peripheral Neuropathy is a disease that has an adverse affect on the health of millions of people worldwide....

Allsup Observes May as Arthritis Awareness Month

2013-05-16 23:01:19

Arthritis affects more than 21 million Americans; Allsup representatives can assist individuals with arthritis in applying for Social Security Disability Insurance benefits. Belleville, Ill. (PRWEB) May 16, 2013 Arthritis limits the activities of nearly 21 million adults in the U.S. and is the nation’s leading cause of disability, according to the Centers for Disease Control and Prevention (CDC). The condition also encompasses more than 100 rheumatic diseases that affect the joints and...

Scleroderma Experts from Johns Hopkins, Northwestern and Stanford to Explain Symptoms and Treatment Options

2013-05-16 12:30:22

A Free Webinar provided by the Scleroderma Research Foundation with support from Gilead Sciences, MedImmune and Novartis SAN FRANCISCO, May 16, 2013 /PRNewswire-USNewswire/ -- The nonprofit Scleroderma Research Foundation (SRF) will welcome Drs. Monique Hinchcliff, Lorinda Chung and Laura Hummers as featured speakers for the popular webinar series helping patients and caregivers to better understand the disease as well as what is being done to find a cure and what new treatments are...

LRI National Patient Coalition Advocacy Culminates in Launch of Federal Provider Education Program

2013-05-16 12:27:22

Singer Toni Braxton Shares Personal Story of Lupus NEW YORK, May 16, 2013 /PRNewswire/ -- The Lupus Research Institute (LRI) National Patient Coalition participated in today's launch of the Lupus Initiative(®), the culmination of its five-year advocacy campaign resulting in $4.6 million in Federal funding to make the healthcare provider education program possible. Helping to draw attention to the need addressed by the Initiative to train professionals in lupus diagnosis, six-time...

SIMPONI® (golimumab) Receives FDA Approval for Ulcerative Colitis

2013-05-15 16:28:06

First and Only Subcutaneous Biologic Treatment Approved to Induce and Maintain Clinical Response and Improve Endoscopic Appearance of the Mucosa During Induction HORSHAM, Pa., May 15, 2013 /PRNewswire/ -- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI(®) (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have demonstrated corticosteroid dependence or who have had an...

Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn's Disease

2013-05-15 08:29:48

PRINCETON, N.J., May 15, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease. The program has...

The Lupus Foundation Of America Turns New York's Attention To A 'Cruel Mystery' That Affects Millions Of Americans

2013-05-14 12:30:59

May is Lupus Awareness Month; Walk, Purple Bus with Interactive Experience, and Education Events Taking Place in New York City NEW YORK, May 14, 2013 /PRNewswire-USNewswire/ -- In recognition of Lupus Awareness Month, the Lupus Foundation of America is hosting a number of programs throughout New York City where New Yorkers can join the efforts to raise awareness of lupus and solve the cruel mystery of the disease. Lupus is a mysterious and devastating autoimmune disease that ravages...

AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease

2013-05-14 08:34:47

AbbVie secures exclusive option to acquire global rights to ALV003 NORTH CHICAGO, Ill. and SAN CARLOS, Calif., May 14, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Alvine Pharmaceuticals, a leader in celiac disease therapeutics development, announced today that they have entered into a global collaboration to develop a novel oral treatment for patients with celiac disease, currently in Phase 2 development. This collaboration builds on AbbVie's expertise and leadership in the field...